VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | Distinguishing between de novo AML and secondary AML using mutational signatures

Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, shares some insights into the importance of distinguishing between de novo acute myeloid leukemia (AML) and secondary AML using specific mutational signatures, and how this can be carried out in clinical practice. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter